Tech Company Financing Transactions
Celsense Funding Round
Private investors participated in a $2 million Series B funding round for Celsense. This venture round was announced by the company on 4/22/2008.
Transaction Overview
Company Name
Announced On
4/22/2008
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series B
Investors
Proceeds Purpose
"In late 2007 we commenced the process of toxicity testing for Cell Sense, with the goal of opening a Drug Master File in 2008. The proceeds of this transaction will permit the company to complete those studies this year," said Aaron Nelson, Director of Regulatory Affairs.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
603 Stanwix St. 348
Pittsburgh, PA 15222
USA
Pittsburgh, PA 15222
USA
Phone
Website
Email Address
Overview
Out of business.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Paul Kornblith
Chief Executive Officer
Charles O'Hanlon
Chief Scientific Officer
Eric Ahrens
Browse more venture capital transactions:
Prev: 4/22/2008: Resolvyx Pharmaceuticals venture capital transaction
Next: 4/22/2008: SolarOne Solutions venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs